OrbiMed

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

2 Sept 2025

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

Charm Therapeutics develops next generation cancer drugs designed to overcome treatment resistance, using an AI driven discovery platform to identify compounds for aggressive blood cancers such as AML.

OrbiMed

- Life Sciences
1(12 months)
orbimed.com
Update Information

More venture news

Wordsmith AI
3 Jun 2026
Wordsmith raises £55m Series B from Highland Europe and Index Ventures to bring end-to-end operations platform to in-house legal teams
Series BLegal
Orbital Industries
28 May 2026
Orbital Industries lands £37m Series B led by Plural to build data centre hardware with AI model
Series BAI
RemotePass
20 May 2026
RemotePass unlocks £13m Series B led by EBRD VC for cross-border payroll and workforce management platform
Series BEnterprise

OrbiMed

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

More venture news

Wordsmith raises £55m Series B from Highland Europe and Index Ventures to bring end-to-end operations platform to in-house legal teams

Orbital Industries lands £37m Series B led by Plural to build data centre hardware with AI model

RemotePass unlocks £13m Series B led by EBRD VC for cross-border payroll and workforce management platform